Title
Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) Trial: A randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery
Date Issued
01 August 2006
Access level
metadata only access
Resource Type
journal article
Author(s)
Devereaux P.J.
Ciapponi A.
Dieguez M.
Granel A.
Barratt S.
Beilby D.
Bolsin S.
Grant J.
Kerridge R.
Love J.
McCulloch T.
Myles P.
Paech M.
Peyton P.
Priestley M.
Halliwell R.
Reeves M.
Varigos J.
Wolfers D.
de Albuquerque D.
do Amaral Baruzzi A.C.
Blacher C.
Carlos Bodanese L.
Pericles Esteves J.
Lucio Alves Bapista Filho M.
Eduardo Guiselli Gallina L.
Mitsuru Izukawa N.
Nigro Maia L.
Antonio Marin-Neto J.
Ribeiro Franca Neto O.
Rabello R.
Henrique Penha Rosateli P.
Francisco Kerr Saraiva J.
Ali N.
Badner N.
Baer C.
Beattie S.
Bertozzi H.
Brunet D.
Bryson G.
Campeau J.
Chauret D.
Cook D.
Cook D.
Davies B.
Doak G.
Doig G.
Dresser G.
Duffy P.
Findlayson A.
Ghali W.
Gilbert K.
Hughes D.
Jacka M.
Kamra C.
Khurana M.
Lanthier L.
Lazaric D.
MacDonald C.
MacDonald P.
Marti J.
Martinek R.
Merchant R.
Miller D.
Misterski J.
Mizera R.
Morin J.
Parlow J.
Paul J.
O'Reilly M.
Ostrander J.
Rammohan S.
Rosen C.
Schricker T.
Sivakamaran S.
Turabian M.
Twist D.
VanVlymen J.
Warriner B.
Wong D.
Zarnke K.
Chen W.
Chen W.
Cui J.Y.
Deng L.L.
Hu W.J.
Guan W.
Jiang B.
Li H.Y.
Li J.
Li X.
Li Z.
Liu H.L.
Liu J.H.
Liu L.H.
Liu Y.D.
Ma S.P.
Ren F.X.
Sun L.
Wang C.P.
Publisher(s)
Mosby Inc.
Abstract
Background: Noncardiac surgery is associated with significant cardiovascular mortality, morbidity, and cost. Small trials of β-blockers suggest that they may prevent cardiovascular events in patients undergoing noncardiac surgery, but trial results are inconclusive. We have initiated the POISE trial to definitively establish the effects of β-blocker therapy in patients undergoing noncardiac surgery. Methods: The POISE trial is a blinded, randomized, and controlled trial of controlled-release metoprolol versus placebo in 10000 patients at risk for a perioperative cardiovascular event who are undergoing noncardiac surgery. Patients will receive the study drug 2 to 4 hours before surgery and subsequently for 30 days. The primary outcome is a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal cardiac arrest at 30 days. Patients will also be followed for events at 1 year. Results: To date, the POISE trial has recruited >6300 patients in 182 centers in 21 countries. Currently, the patients' mean age is 69 years; 63% are males, 43% have a history of coronary artery disease, 43% have a history of peripheral arterial disease, and 30% have diabetes. Most participants have undergone vascular (42%), intraabdominal (23%), or orthopedic (19%) surgery. Conclusions: The POISE trial is a large international trial that will provide a reliable assessment of the effects of β-blocker therapy in patients undergoing noncardiac surgery.
Start page
223
End page
230
Volume
152
Issue
2
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular
Epidemiología
Scopus EID
2-s2.0-33746266569
PubMed ID
Source
American Heart Journal
ISSN of the container
00028703
Sponsor(s)
Grants from the Canadian Institutes of Health Research, the Commonwealth Government of Australia's National Health and Medical Research Council, and the British Heart Foundation provide the funds for the POISE trial. AstraZeneca (Mississauga, Ontario, Canada) has provided the study drug and funding for drug labeling, packaging, and shipping.
Sources of information:
Directorio de Producción Científica
Scopus